{{Infobox disease 
 | Name            = Primary effusion lymphoma 
 | Image           = 
 | Caption         = 
 | DiseasesDB      = 33904 
 | ICD10           = 
 | ICD9            = 
 | ICDO            = {{ICDO|9678|3}} 
 | OMIM            = 
 | MedlinePlus     = 
 | eMedicineSubj   = 
 | eMedicineTopic  = 
 | MeshID          = D054685 
}}
'''Primary effusion lymphoma''' (PEL) is a [[B-cell lymphoma]].<ref>{{DorlandsDict|nine/10098969|primary effusion lymphoma}}</ref>

==Causes==
It is caused by [[Kaposi's sarcoma-associated herpesvirus]] (KSHV), also known as human herpesvirus 8 (HHV-8).<ref>{{cite journal |author=Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM |title=Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas |journal=N. Engl. J. Med. |volume=332 |issue=18 |pages=1186–91 |year=1995 |month=May |pmid=7700311 |doi= 10.1056/NEJM199505043321802|url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=7700311&promo=ONFLNS19}}</ref><ref>{{cite journal |author=Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP |title=The tumor microenvironment controls primary effusion lymphoma growth in vivo |journal=Cancer Res. |volume=64 |issue=14 |pages=4790–9 |year=2004 |month=July |pmid=15256448 |doi=10.1158/0008-5472.CAN-03-3835 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15256448}}</ref>

In most cases, the lymphoma cells are also infected with [[Epstein Barr virus]] (EBV).<ref name="pmid15613351">{{cite journal |author=Fan W, Bubman D, Chadburn A, Harrington WJ, Cesarman E, Knowles DM |title=Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association |journal=J. Virol. |volume=79 |issue=2 |pages=1244–51 |year=2005 |month=January |pmid=15613351 |pmc=538532 |doi=10.1128/JVI.79.2.1244-1251.2005 |url=http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=15613351}}</ref>

PEL most commonly arises in patients with underlying [[immunodeficiency]], such as [[AIDS]].<ref>{{cite journal |author=Boshoff C, Weiss R |title=AIDS-related malignancies |journal=Nat. Rev. Cancer |volume=2 |issue=5 |pages=373–82 |year=2002 |month=May |pmid=12044013 |doi=10.1038/nrc797}}</ref><ref>{{cite journal |author=Yarchoan R, Tosato G, Little RF |title=Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management |journal=Nat Clin Pract Oncol |volume=2 |issue=8 |pages=406–15; quiz 423 |year=2005 |month=August |pmid=16130937 |doi= 10.1038/ncponc0253|url=}}</ref>

The condition can exist in the absence of HHV-8 and HIV, though this is rare.<ref name="pmid16364944">{{cite journal |author=Youngster I, Vaisben E, Cohen H, Nassar F |title=An unusual cause of pleural effusion |journal=Age Ageing |volume=35 |issue=1 |pages=94–6 |year=2006 |month=January |pmid=16364944 |doi=10.1093/ageing/afj009 |url=http://ageing.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16364944}}</ref>

==Presentation==
PEL is unusual in that the majority of cases arise in body cavities, such as the [[pleural]] space or the [[pericardium]]; another name for PEL is "body cavity lymphoma".

A case has been described that was positive for [[CD38]], [[CD71]] and [[CD30]].<ref name="urlCase 98-3 - AIDS-Related Primary Effusion Lymphoma">{{cite web |url=http://www.healthsystem.virginia.edu/internet/pathology/casestudies/heme/k98_3.cfm |title=Case 98-3 - AIDS-Related Primary Effusion Lymphoma |format= |work= |accessdate=}}</ref> Positive also for CD45 (LCA), CD138, MUM-1 but negative for CD20, CD79a and PAX-5.

==History==
It was recognized as a unique type of lymphoma only after the discovery of KSHV in 1994.

==Prognosis==
It is generally resistant to cancer [[chemotherapy]] drugs that are active against other lymphomas, and carries a poor prognosis.<ref name="pmid17522245">{{cite journal |author=Chen YB, Rahemtullah A, Hochberg E |title=Primary effusion lymphoma |journal=Oncologist |volume=12 |issue=5 |pages=569–76 |year=2007 |month=May |pmid=17522245 |doi=10.1634/theoncologist.12-5-569 |url=http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=17522245}}</ref>

[[Sirolimus]] has been proposed as a treatment option.<ref name="pmid17082322">{{cite journal |author=Sin SH, Roy D, Wang L, ''et al.'' |title=Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling |journal=Blood |volume=109 |issue=5 |pages=2165–73 |year=2007 |month=March |pmid=17082322 |pmc=1801055 |doi=10.1182/blood-2006-06-028092 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=17082322}}</ref>

==See also==
* [[List of hematologic conditions]]

==References==
{{reflist|2}}

{{Hematological malignancy histology}}

[[Category:Lymphoma]]